# Causaly

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/causaly

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.causaly.com
- Total disclosed funding: $90M
- Latest round: Series B (Jul 13, 2023)
- Investors on record: 6

## About

Causaly Ltd., based in the UK, develops a pioneering AI platform tailored for the life sciences sector, enhancing the research capabilities of pharmaceutical and biotech organizations.Founded in 2018 and headquartered in London, UK, Causaly Ltd. specializes in providing advanced AI solutions for biomedical research. The company has conducted a total of 4 funding deals, with their most recent being a Series B round on July 13, 2023, raising EUR 60.00 mn, led by ICONIQ Capital and supported by investors including EBRD, Index Ventures, Marathon Venture Capital, Pentech Ventures, and Visionaries Club. The founders, Artur Saudabayev and Yiannis Kiachopoulos, have leveraged their expertise to drive the company’s growth.Causaly offers a comprehensive AI platform designed specifically for the life sciences sector. Its core product is a high-precision knowledge graph that integrates advanced artificial intelligence to enhance biomedical research. This platform enables users to efficiently retrieve complex biomedical information, providing reliable responses backed by inline citations. Key functionalities include identifying and prioritizing research targets, unraveling complex disease biology, and advancing biomarker research. The company serves a diverse clientele within the pharmaceutical and biotech sectors, including research scientists and data analysts across North America, Europe, and Asia, facilitating a unified data source for R&D teams.Causaly primarily generates revenue through subscription-based models for its AI platform, allowing organizations to access a suite of tools and analytics. This structure ensures clients receive ongoing updates and enhancements. Their flagship offerings, including the knowledge graph and a scientific AI copilot, address the specific needs of research teams, improving productivity and decision-making in drug development. Engagements are typically B2B, where pharmaceutical and biotech firms incorporate Causaly’s solutions into their research workflows, fostering long-term partnerships essential for innovation in life sciences.In July 2023, Causaly Ltd. secured EUR 60.00 mn in Series B funding to establish commercial partnerships and enhance its market presence. The company is focused on expanding its offerings, potentially unveiling new products to further support research capabilities in the life sciences. Additionally, they plan to penetrate new geographic markets, with specific emphasis on regions yet to be defined, by leveraging this recent investment to bolster their strategic initiatives.

## Funding rounds

- Series B, Jul 13, 2023, $67M — Index Ventures, Pentech Ventures, ICONIQ Capital, EBRD, Marathon Venture Capital, Visionaries Club
- Series A, May 7, 2021, $17M — Index Ventures, Pentech Ventures, EBRD, Marathon Venture Capital
- Series A, Nov 19, 2019, $4.8M — Pentech Ventures, EBRD, Marathon Venture Capital
- Seed, Jul 26, 2018, $1M — Marathon Venture Capital

## Investors

- Marathon Venture Capital (https://capitalatlas.ai/funds/marathon-venture-capital) — Seed, Series A, Series B
- Pentech Ventures (https://capitalatlas.ai/funds/pentech-ventures) — Series A, Series B
- EBRD (https://capitalatlas.ai/funds/ebrd) — Series A, Series B
- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series B
- ICONIQ Capital (https://capitalatlas.ai/funds/iconiq-capital) — Series B
- Visionaries Club (https://capitalatlas.ai/funds/visionaries-club) — Series B